Selective inhibition of interleukin-2 inducible T cell kinase (ITK) enhances anti-tumor immunity in association with Th1-skewing, cytotoxic T cell activation, and reduced T cell exhaustion
Hsu, L.-Y.; Rosenbaum, J. T.; Verner, E.; Jones, W. B.; Hill, C. M.; Janc, J. W.; Buggy, J. J.; Ding, N.; Reneau, J. C.; Khodadoust, M. S.; Kim, Y. H.; Wilcox, R. A.; Miller, R. A.
Show abstract
ITK is a tyrosine kinase expressed predominantly by T lymphocytes. In mice, selective knock-out of the ITK gene produces Th1 skewing of T helper cell differentiation. We synthesized a covalent ITK inhibitor, soquelitinib, that binds ITK with greater than 100-fold selectivity compared to binding to resting lymphocyte kinase (RLK). In vitro studies with normal or malignant T cells demonstrated that soquelitinib suppresses Th2 cytokine production preferentially with relative sparing of Th1 cytokines. Soquelitinib inhibits the in vivo growth of several syngeneic murine tumors including those that do not express ITK. Treatment with soquelitinib leads to increased tumor infiltration of normal CD8+ cells that possess enhanced T effector function. Soquelitinib inhibited expression of T cell exhaustion markers and was able to restore T effector function to exhausted cells. Pharmacologic selective ITK inhibition may represent a novel approach to cancer immunotherapy.
Matching journals
The top 12 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity 94%
- Domain Binding and Isotype Dictate the Activity of Anti-human OX40 Antibodies 94%
- Combination of oncolytic Maraba virus with immune checkpoint blockade overcomes therapy resistance in an immunologically cold model of advanced melanoma with dysfunctional T cell receptor signalling. 94%
Similar papers in this journal
- Targeting aggressive B-cell lymphomas through pharmacological activation of the mitochondrial protease OMA1 95%
- ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms 94%
- Development of antibody-drug conjugates targeting L1CAM to treat metastatic cancer 94%
Similar papers in this journal
- PTPRZ1-targeting RNA CAR-T cells exert antigen-specific and bystander antitumor activity in glioblastoma 95%
- Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory 95%
- Preclinical Characterization of Relatlimab, a Human LAG-3-Blocking Antibody, Alone or in Combination With Nivolumab 94%
Similar papers in this journal
- The PKN1- TRAF1 signaling axis as a potential new target for chronic lymphocytic leukemia 95%
- CD4+ tumor-infiltrating lymphocytes secreting T cell-engagers induce regression of autologous patient-derived non-small cell lung cancer xenografts 95%
- Patient-derived tumor explant models of tumor immune microenvironment reveal distinct and reproducible immunotherapy responses 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.